Search Results - "Fryatt, I"

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds by Gore, M E, Fryatt, I, Wiltshaw, E, Dawson, T

“…Fifty-four patients with ovarian cancer who achieved a complete or partial remission with cisplatin or carboplatin were rechallenged with the same drug or…”
Get more information

Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer by Taylor, A E, Wiltshaw, E, Gore, M E, Fryatt, I, Fisher, C

“…A phase III trial was performed between October 1981 and June 1984 to compare the efficacy of single-agent cisplatin and single-agent carboplatin in previously…”
Get more information

Limitations of surgery in the treatment of retroperitoneal sarcoma by Alvarenga, J C, Ball, A B, Fisher, C, Fryatt, I, Jones, L, Thomas, J M

“…A retrospective analysis was undertaken of 120 patients with retroperitoneal sarcoma referred to the Royal Marsden Hospital over a period of 20 years. The…”
Get more information

Cisplatin/carboplatin cross-resistance in ovarian cancer by GORE, M. E, FRYATT, I, WILTSHAW, E, DAWSON, T, ROBINSON, B. A, CALVERT, A. H

“…Forty-six patients who were treated with cisplatin or carboplatin for ovarian cancer developed resistant disease (no change in measurable disease or…”
Get full text

The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma by Hawkins, R E, Roberts, K, Wiltshaw, E, Mundy, J, Fryatt, I J, McCready, V R

“…Various prognostic factors were studied in 29 patients with stage III or IV ovarian cancer who responded to initial chemotherapy after initial diagnostic…”
Get more information

A matched control study of familial epithelial ovarian cancer: patient characteristics, response to chemotherapy and outcome by Chang, J, Fryatt, I, Ponder, B, Fisher, C, Gore, M E

“…Many of the characteristics of patients with familial epithelial ovarian cancer (EOC) are not yet well defined. This report describes some of the…”
Get more information

Treatment of extremity soft tissue sarcomas with surgery and radiotherapy by Robinson, M, Barr, L, Fisher, C, Fryatt, I, Stotter, A, Harmer, C, Wiltshaw, E, Westbury, G

“…The results of treatment with a combination of surgery and radiotherapy of 102 patients with nonmetastatic extremity soft tissue sarcoma are reported…”
Get more information

Omental transposition in the treatment of locally advanced and recurrent breast cancer by Williams, R J, Fryatt, I J, Abbott, W C, White, H

“…An analysis was carried out of 43 patients treated by omental transposition for locoregional problems associated with breast cancer. Indications for surgery…”
Get more information

Hormone replacement therapy and survival after surgery for ovarian cancer by Eeles, R A, Tan, S, Wiltshaw, E, Fryatt, I, A'Hern, R P, Shepherd, J H, Harmer, C L, Blake, P R, Chilvers, C E

“…OBJECTIVE--To evaluate whether hormone replacement therapy affects survival in women who have undergone bilateral salphingo-oophorectomy because of epithelial…”
Get full text

Steroid hormone profile in postmenopausal women with ovarian cancer by O'Brien, M E, Dowsett, M, Fryatt, I, Wiltshaw, E

“…Raised levels of steroid hormones are not expected in postmenopausal women. Therefore, if detected in postmenopausal women with ovarian cancer, they must be…”
Get more information

Computerized axial tomographic scan measurements as prognostic indicators in patients with cervical carcinoma by Shepherd, S F, Collins, C D, Fryatt, I J, Parsons, C A, Blake, P R

“…This retrospective study of 56 patients with carcinoma of the uterine cervix treated with radical radiotherapy at the Royal Marsden Hospital, London, examined…”
Get more information

Factors influencing local recurrence and survival in patients with soft tissue sarcoma of the upper limb by Serpell, J W, Ball, A B, Robinson, M H, Fryatt, I, Fisher, C, Thomas, J M

“…Fifty-one patients with soft tissue sarcoma of the upper limb were studied to identify risk factors for local recurrence and survival. More than half (53 per…”
Get more information

A randomized cross-over study of the efficacy of codeine phosphate versus Ispaghulahusk in patients with gynaecological cancer experiencing diarrhoea during pelvic radiotherapy by Lodge, N, Evans, M L, Wilkins, M, Blake, P R, Fryatt, I

“…Diarrhoea is the commonest acute complication during radiotherapy treatment to the pelvis. Codeine phosphate and a low residue diet is the standard therapy for…”
Get more information

How nephrotoxic is carboplatin? by Hardy, J R, Tan, S, Fryatt, I, Wiltshaw, E

Get full text

Is there still a role for lymphography in the management of early stage carcinoma of the cervix? by Fernando, I N, Moskovic, E, Fryatt, I, Glaholm, J, Blake, P R

“…The value of lymphography in the management of carcinoma of the cervix is controversial and in many institutions has ceased to be used as part of routine…”
Get more information

Relationship of computed tomography tumour volume to patient survival in carcinoma of the cervix treated by radical radiotherapy by Collins, C D, Constant, O, Fryatt, I, Blake, P R, Parsons, C A

“…In this retrospective study tumour volume was calculated by two different methods from the staging computed tomographic scans obtained in 1987 of 20 patients…”
Get more information

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group by Perren, T J, Wiltshaw, E, Harper, P, Slevin, M, Stein, R, Tan, S, Gore, M, Fryatt, I J, Blake, P R

“…In a study designed to compare response rates of patients with stage III epithelial ovarian carcinoma to ifosfamide and carboplatin, 152 patients were…”
Get full text

Carboplatin and ifosfamide in ovarian cancer phase II and III trials by WILTSHAW, E, PERREN, T. J, FRYATT, I. D, BLAKE, P. R, HARPER, P, SLEVIN, M

Get full text

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma by PERREN, T. J, WILTSHAW, E, HARPER, P, SLEVIN, M, STEIN, R, TAN, S, GORE, M, FRYATT, I. J, BLAKE, P. R

Get full text

Is delayed treatment justified in carcinoma of the prostate? by Parker, M C, Cook, A, Riddle, P R, Fryatt, I, O'Sullivan, J, Shearer, R J

“…We report a retrospective survey of 263 patients with prostate cancer presenting between 1975 and 1979, with a minimum follow-up period of 5 years. We have…”
Get more information